Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Anesthesiology Reports
Published in: Current Anesthesiology Reports 4/2018

01-12-2018 | Cancer Anesthesia (B Riedel and V Gottumukkala, Section Editors)

Perioperative Stress, Inflammation, and Cancer Progression: Opportunities for Intervention in Breast and Colorectal Cancer Surgery Utilizing Beta-Adrenergic Blockade and COX-2 Inhibition

Authors: Avital Fischer, Shamgar Ben-Eliyahu

Published in: Current Anesthesiology Reports | Issue 4/2018

Login to get access

Abstract

Purpose of review

This review explores the blockade of cyclooxygenase (COX)-2/prostaglandin and catecholamine/beta(β)-adrenergic signaling as opportunities to enhance the curative potential of surgical excision of breast and colorectal cancer malignancies.

Recent findings

Phase-II randomized placebo-controlled biomarker clinical trials, employing perioperative administration of the COX-2 inhibitor etodolac and the β-adrenergic antagonist propranolol, have shown improved biomarkers associated with both breast and colorectal cancer progression. Tumor epithelial-to-mesenchymal transition (EMT) status and tumor transcription activity levels of GATA-1, GATA-2, EGR3, and STAT-3 were reduced, while anti-cancer immune parameters within the tumor microenvironment improved perioperatively. Increased tumor-associated B cells and NK cells and reduced tumor-associated monocytes were noted. Reduced systemic pro-inflammatory markers IL-6 and CRP were indicated, starting before surgery.

Summary

Improved biomarkers of tumor-associated (i) anti-metastatic transcriptional activity, (ii) anti-metastatic immune function, and (iii) reduced systemic inflammatory indices were observed following the combined administration of etodolac and propranolol. These findings support future investigation with larger clinical trials to test long-term cancer outcomes.
Literature
1.
Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene. 2010;29:781–8.PubMed
2.
Gottschalk A, Sharma S, Ford J, Durieux ME, Tiouririne M. The role of the perioperative period in recurrence after cancer surgery. Anesth Analg. 2010;110:1636–43.PubMed
3.
Glasner A, Avraham R, Rosenne E, Benish M, Zmora O, Shemer S, et al. Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a β-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J Immunol. 2010;184:2449–57.
4.
Neeman E, Ben-Eliyahu S. Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement. Brain Behav Immun. 2013;30(Suppl):S32–40.PubMed
5.
• Horowitz M, Neeman E, Sharon E, Ben-Eliyahu S. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nat Publ gr. 2015;12:213–26 This review discusses the underlying pro-metastatic mechanisms of the perioperative timeframe.
6.
Hiller JG, Perry NJ, Poulogiannis G, Riedel B, Sloan EK. Perioperative events influence cancer recurrence risk after surgery. Nat Rev Clin Oncol. 2018;15:205–18.PubMed
7.
Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol. 2003;10:972–92.PubMed
8.
Ben-Eliyahu S, Golan T. Harnessing the Perioperative Period to Improve Long-term Cancer Outcomes. JNCI J Natl Cancer Inst. 2018;110:1137–1138.
9.
10.
Ricon I, Hanalis-Miller T, Haldar R, Jacoby R, Ben-Eliyahu S. Perioperative Biobehavioral Interventions to Prevent Cancer Recurrence Through Combined Inhibition of β-Adrenergic and Cyclooxygenase 2 Signaling. Cancer. 2018. https://​doi.​org/​10.​1002/​cncr.​31594
11.
Yamaguchi K, Takagi Y, Aoki S, Futamura M, Saji S. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann Surg. 2000;232:58–65.PubMedPubMedCentral
12.
Choy A, Mcculloch P. Induction of tumour cell shedding into effluent venous blood breast cancer surgery. Br J Cancer. 1996;73:79–82.PubMedPubMedCentral
13.
Benish M, Bartal I, Goldfarb Y, Levi B, Avraham R, Raz A, et al. Perioperative use of β-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol. 2008;15:2042–52.
14.
Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res. 1989;49:1996–2001.PubMed
15.
O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994;79:315–28.
16.
O’reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth result of a net balance between these positive and negative regulators of neovascularization Rastinejad et al. Cell. 1997;88:277–85.
17.
Rastinejad F, Polverini PJ, Bouck NP. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell. 1989;56:345–55.PubMed
18.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.PubMed
19.
20.
Elenkov I, Wilder R, Chrousos GP, Vizi S. The sympathetic nerve—an integrative Interface between two supersystems: the brain and the immune system ILIA. Pharmacol Rev. 2000;52:63–89.
21.
Buvanendran A, Kroin JS, Berger RA, Hallab NJ, Saha C, Negrescu C, et al. Upregulation of prostaglandin E2 and interleukins in the central nervous system and peripheral tissue during and after surgery in humans. Anesthesiology. 2006;104:403–10.
22.
Reader J, Holt D, Fulton A. Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev. 2011;30:449–63.PubMedPubMedCentral
23.
Legler DF, Bruckner M, Uetz-von Allmen E, Krause P. Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances. Int J Biochem Cell Biol. 2010;42:198–201.PubMed
24.
Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 2002;8:289–93.PubMed
25.
Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostaglandin E 2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem. 2003;278:35451–7.PubMed
26.
Wang D, Wang H, Shi Q, Katkuri S, Walhi W, Desvergne B, et al. Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor δ. Cancer Cell. 2004;6:285–95.
27.
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705–16.PubMed
28.
Wang D, Buchanan FG, Wang H, Dey SK, DuBois RN. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res. 2005;65:1822–9.PubMed
29.
30.
Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998;58:362–6.PubMed
31.
Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063–73.
32.
Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:83–1188.
33.
Howe LR. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res. 2007;9:210.PubMedPubMedCentral
34.
Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, et al. Genetic disruption of Ptgs-1, as well as of Ptgs-2, reduces intestinal tumorigenesis in min mice. Cancer Res. 2000;60:4705–8.
35.
• Hugo HJ, Saunders C, Ramsay RG, Thompson EW. New insights on COX-2 in chronic inflammation driving breast cancer growth and metastasis. J Mammary Gland Biol Neoplasia. 2015. https://​doi.​org/​10.​1007/​s10911-015-9333-4Review of the role of COX-2 signaling in breast cancer progression.
36.
37.
Glover J, Hughes C, Cantwell M, Murray L. A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancer. Br J Cancer. 2011;105:13–7.PubMedPubMedCentral
38.
39.
Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 Expression: A Significant Prognostic Indicator for Patients With Colorectal Cancer. Clin Cancer Res 2004;10:8465–8471.
40.
Pérez-Sayáns M, Somoza-Martín JM, Barros-Angueira F, Diz PG, Gándara Rey JM, García-García A. Beta-adrenergic receptors in cancer: therapeutic implications. Oncol Res. 2010;19:45–54.PubMed
41.
Chida Y, Hamer M, Wardle J, Steptoe A. Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Clin Pr Oncol. 2008;5:466–75.
42.
Antoni MH, Cole SW. The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Michael. 2011;6:240–8.
43.
Nilsson MB, Armaiz-Pena G, Takahashi R, Lin YG, Trevino J, Li Y, et al. Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem. 2007;282:29919–26.
44.
45.
46.
Drell Iv TL, Joseph J, Lang K, Niggemann B, Zaenker KS, Entschladen F. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat. 2003;80:63–70.
47.
Masur K, Niggemann B, Zanker KS, Entschladen F. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res. 2001;61:2866–9.PubMed
48.
Friedl P, Maaser K, Klein CE, Niggemann B, Krohne G, Zänker KS. Migration of highly aggressive MV3 melanoma cells in 3-dimensional collagen lattices results in local matrix reorganization and shedding of alpha2 and beta1 integrins and CD44. Cancer Res. 1997;57:2061–70.PubMed
49.
Chen H, Liu D, Yang Z, Sun L, Deng Q, Yang S, et al. Adrenergic signaling promotes angiogenesis through endothelial cell-tumor cell crosstalk. Endocr Relat Cancer. 2014;21:783–95.
50.
Park SY, Kang JH, Jeong KJ, Lee J, Han JW, Choi WS, et al. Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1α protein-dependent mechanism. Int J Cancer. 2011;128:2306–16.
51.
Sastry KSR, Karpova Y, Prokopovich S, Smith AJ, Essau B, Gersappe A, et al. Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation. J Biol Chem. 2007;282:14094–100.
52.
Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest. 2010;120:1515–23.
53.
Heaney Á, Buggy DJ. Can anaesthetic and analgesic techniques affect cancer recurrence or metastasis? Br J Anaesth. 2012;109:i17–28.PubMed
54.
Schlagenhauff B, Ellwanger U, Breuninger H, Stroebel W, Rassner G, Garbe C. Prognostic impact of the type of anaesthesia used during the excision of primary cutaneous melanoma. Melanoma Res. 2000;10:165–9.PubMed
55.
Deegan CA, Murray D, Doran P, Ecimovic P, Moriarty DC, Buggy DJ. Effect of anaesthetic technique on oestrogen receptor-negative breast cancer cell function in vitro †. Br J Anaesth. 2009;103:685–90.PubMed
56.
Bayer BM, Daussin S, Hernandez M, Irvin L. Morphine inhibition of lymphocyte activity is mediated by an opioid dependent mechanism. Neuropharmacology. 1990;29:369–74.PubMed
57.
Afsharimani B, Doornebal CW, Cabot PJ, Hollmann MW, Parat M-O. Comparison and analysis of the animal models used to study the effect of morphine on tumour growth and metastasis. Br J Pharmacol. 2015;172:251–9.PubMed
58.
Gaspani L, Bianchi M, Limiroli E, Panerai AE, Sacerdote P. The analgesic drug tramadol prevents the effect of surgery on natural killer cell activity and metastatic colonization in rats. J Neuroimmunol. 2002;129:18–24.PubMed
59.
60.
61.
Kurz A, Sessler DI, Lenhardt R. Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization. N Engl J Med. 1996;334:1209–16.PubMed
62.
Nduka CC, Puttick M, Coates P, Yong L, Peck D, Darzi A. Intraperitoneal hypothermia during surgery enhances postoperative tumor growth. Surg Endosc. 2002;16:611–5.PubMed
63.
Shamgar B-E, Shakhar G, Rosenne E, Levinson Y, Beilin B. Hypothermia in barbiturate-anesthetized rats suppresses natural killer cell activity and compromises resistance to tumor metastasis a role for adrenergic mechanisms. Anesthesiol J Am Soc Anesthesiol. 1999;91:732–2.
64.
65.
Acheson AG, Brookes MJ, Spahn DR. Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta-analysis. Ann Surg. 2012;256:235–44.PubMed
66.
Lenhard V, Maassen G, Opelz G. Transfusion-induced enhancement of prostaglandin and thromboxane release in prospective kidney graft recipients. Proc Eur Dial Transplant Assoc Eur Ren Assoc. 1985;21:923–7.PubMed
67.
Melamed R, Rosenne E, Shakhar K, Schwartz Y, Abudarham N, Ben-Eliyahu S. Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a β-adrenergic antagonist and a prostaglandin synthesis inhibitor. Brain Behav Immun. 2005;19:114–26.PubMed
68.
•• Liat S, Rivka M, Pini M, Hagar L, Lee S, Ella R, Shamgar B-E Reducing liver metastases of colon cancer in the context of extensive and minor surgeries through β-adrenoceptors blockade and COX2 inhibition HHS Public Access. 2016. https://​doi.​org/​10.​1016/​j.​bbi.​2016.​05.​017. Preclinical animal study demonstrating the biological plausability of improved colorectal cancer outcomes with perioperative β-adrenoceptors blockade and COX2 inhibition.
69.
Yakar I, Melamed R, Shakhar G, Shakhar K, Rosenne E, Abudarham N, et al. Prostaglandin e(2) suppresses NK activity in vivo and promotes postoperative tumor metastasis in rats. Ann Surg Oncol. 2003;10:469–79.
70.
71.
Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol. 2011;29:2635–44.PubMed
72.
Powe DG, Voss MJ, Zänker KS, Habashy HO, Green AR, Ellis IO, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget. 2010;1:628–38.
73.
Kim HY, Jung YJ, Lee SH, Jung HJ, Pak K. Clinical study is Beta-blocker use beneficial in breast cancer? A meta-analysis. Oncology. 2017;92:264–8.PubMed
74.
• Desmedt C, Demicheli R, Fornili M, et al. Potential benefit of intra-operative administration of ketorolac on breast cancer recurrence according to the patient’s body mass index. JNCI J Natl Cancer Inst. 2018. https://​doi.​org/​10.​1093/​jnci/​djy042. Epidemiological investigation showing the benefit of intra-operative COX-2 blockade using ketorolac on breast cancer recurrence.
75.
Jaffe T, Schwartz B. Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways. Int J Cancer. 2008;123:2543–56.PubMed
76.
Guo Y, Kenney SR, Muller CY, Adams S, Rutledge T, Romero E, et al. R-ketorolac targets Cdc42 and Rac1 and alters ovarian cancer cell behaviors critical for invasion and metastasis HHS public access. Mol Cancer Ther. 2015;14:2215–27.
77.
•• Shaashua L, Shabat-Simon M, Haldar R, et al. Perioperative COX-2 and β-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a phase-II randomized trial. Clin Cancer Res. 2017;23:4651–61 Results of a phase II clinical trial demonstrating the effectiveness of perioperative COX-2 and β-adrenergic blockade in improving breast cancer metastatic biomarkers. PubMedPubMedCentral
78.
Greenfeld K, Avraham R, Benish M, Goldfarb Y, Rosenne E, Shapira Y, et al. Immune suppression while awaiting surgery and following it: dissociations between plasma cytokine levels, their induced production, and NK cell cytotoxicity. Brain Behav Immun. 2007;21:503–13.
79.
Buggy DJ, Borgeat A, Cata J, Doherty DG, Doornebal CW, Forget P, et al. Consensus statement from the BJA workshop on cancer and anaesthesia. Br J Anaesth. 2015;114:2–3.
80.
•• Haldar R, Ricon I, Cole S, Zmora O, Ben-Eliyahu S. Perioperative beta-adrenergic blockade and COX2 inhibition in colorectal cancer patients improves pro-metastatic indices in the excised tumor: EMT, tumor infiltrating lymphocytes (TILs), and gene regulatory pathways. Brain Behav Immun. 2017;66:e9 Results of a phase II clinical trial demonstrating the effectiveness of perioperative COX-2 and β-adrenergic blockade in improving colorectal cancer metastatic biomarkers.
Metadata
Title
Perioperative Stress, Inflammation, and Cancer Progression: Opportunities for Intervention in Breast and Colorectal Cancer Surgery Utilizing Beta-Adrenergic Blockade and COX-2 Inhibition
Authors
Avital Fischer
Shamgar Ben-Eliyahu
Publication date
01-12-2018
Publisher
Springer US
Published in
Current Anesthesiology Reports / Issue 4/2018
Electronic ISSN: 2167-6275
DOI
https://doi.org/10.1007/s40140-018-0295-0

Other articles of this Issue 4/2018

Current Anesthesiology Reports 4/2018 Go to the issue

Cancer Anesthesia (B Riedel and V Gottumukkala, Section Editors)

New Cancer Therapies: Implications for the Perioperative Period

Cancer Anesthesia (B Riedel and V Gottumukkala, Section Editors)

Cancer Tsunami: Emerging Trends, Economic Burden, and Perioperative Implications

Pain Medicine (GJ Meredith, Section Editor)

Considerations in 2017–2018 for the Use of Opioids in Non-terminal Pain

Cancer Anesthesia (B Riedel and V Gottumukkala, Section Editors)

Local Anesthetics (LAs) and Cancer Cell Progression: Is There an Oncologic Protective Role for LAs in Clinical Practice?

Pain Medicine (GJ Meredith, Section Editor)

New Advances in Neuromodulation

Cancer Anesthesia (B Riedel and V Gottumukkala, Section Editors)

Organization of Multidisciplinary Cancer Care for the Surgical Patient: Role of Anesthesiologists